2.1.1.100: protein-S-isoprenylcysteine O-methyltransferase

This is an abbreviated version!
For detailed information about protein-S-isoprenylcysteine O-methyltransferase, go to the full flat file.

Word Map on EC 2.1.1.100

2.1.1.100

n-acetyl-s-farnesyl-l-cysteine

cysmethynil

medicine

a-factor

aax

carboxylmethylation

ste24p

n-acetyl-s-geranylgeranyl-l-cysteine

ras-driven

biotechnology

analysis

drug development

pharmacology

Reaction

S-adenosyl-L-methionine

+

protein C-terminal S-farnesyl-L-cysteine

=

S-adenosyl-L-homocysteine

+

protein C-terminal S-farnesyl-L-cysteine methyl ester

Synonyms

EC 2.1.1.24, farnesyl cysteine C-terminal methyltransferase, farnesyl-protein carboxymethyltransferase, farnesylated protein C-terminal O-methyltransferase, Icmt, isoprenylated protein methyltransferase, isoprenylcysteine carboxyl methyltransferase, isoprenylcysteine carboxylmethyltransferase, isoprenylcysteine carboxylmethyltransferase Ste14p, isoprenylcysteine methylesterase, methyltransferase, protein C-terminal farnesylcysteine O-, prenylated protein methyltransferase, protein S-farnesylcysteine C-terminal methyltransferase, S-farnesylcysteine methyltransferase, STE14A, STE14B, Ste14p

ECTree

2.1 Transferring one-carbon groups

2.1.1 Methyltransferases

2.1.1.100 protein-S-isoprenylcysteine O-methyltransferase

Advanced search results

Do not include text mining results

Include

results (more...)

Include

results (more...)

Results	in table
6	Activating Compound
5180	AA Sequence
16	Application
1	CAS Registry Number
17	Cloned(Commentary)
3	Cofactor
115	Disease/ Diagnostics
2	Expression
13	General Information
2	General Stability
217	IC50 Value
371	Inhibitors
46	Ki Value [mM]
74	KM Value [mM]
33	Localization
2	Metals/Ions
12	Molecular Weight [Da]
21	Natural Substrates/ Products (Substrates)
75	Organism
2	Pathway
2	PDB ID
5	pH Optimum
2	pH Range
1	pH Stability
33	Protein Variants
7	Purification (Commentary)
3	Reaction
1	Reaction Type
74	Reference
61	Source Tissue
3	Specific Activity [micromol/min/mg]
1	Storage Stability
121	Substrates and Products (Substrate)
9	Subunits
88	Synonyms
1	Systematic Name
1	Temperature Optimum [°C]
1	Temperature Range [°C]
3	Turnover Number [1/s]

Inhibitors

print visible entries

print all entries

Go back to the abbreviated version
of the Enzyme Summary Page.

Inhibitors on EC 2.1.1.100 - protein-S-isoprenylcysteine O-methyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.

back to the top

Go to Inhibitor Search

(1-octyl-5-m-tolyl-1H-indol-3-yl)methanamine

-

-

(2R)-2-(acetylamino)-3-[[(2Z)-3,4-diphenylbut-2-en-1-yl]sulfanyl]propanoic acid

-

15.7% inhibition at 0.01 mM

(2R)-2-(acetylamino)-3-[[(2Z)-4-(2-fluorophenyl)-3-phenylbut-2-en-1-yl]sulfanyl]propanoic acid

-

25.3% inhibition at 0.01 mM

(3,5-difluoro-4-methoxyphenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine

-

-

(3-chloro-4-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine

-

-

(3-chlorophenyl)-[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)ethyl]amine

-

-

(4-chloro-3-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine

-

-

(5-chloro-2-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine

-

-

(R)-2-(2-((benzyloxy)methyl)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-thio)propanoic acid

-

-

(R)-2-(2-(phenoxymethyl)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid

-

-

(R)-2-(2-(phenylthio)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid

-

-

(R)-2-(2-benzylbenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid

-

-

(R)-2-(2-phenoxybenzamido)-3-(((2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)thio)propanoic acid

-

-

(R)-2-(2-phenoxybenzamido)-3-(undecylthio)propanoic acid

-

-

(R)-2-(3-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid

-

-

(R)-2-(4-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid

-

-

(R)-2-(dibenzo[b,d]furan-4-carboxamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)-propanoic acid

-

-

(R)-2-(N-methyl-2-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid

-

-

(R,E)-3-((3,7-dimethylocta-2,6-dien-1-yl)thio)-2-(2-phenoxybenzamido)propanoic acid

-

-

(S)-2-(2-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid

-

-

(S)-glabrol

-

structure determination, overview

1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-(3-fluorophenyl)thiourea

-

-

1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-(3-methoxphenyl)urea

-

-

1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-(3-methoxyphenyl)thiourea

-

-

1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-phenylthiourea

-

-

1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-(morpholin-4-ylmethyl)-1H-indole

-

-

1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-(piperidin-1-ylmethyl)-1H-indole

-

-

1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-[(morpholin-4-yl)methyl]-1H-indole

-

-

1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-[(piperidin-1-yl)methyl]-1H-indole

-

-

1-(3-chlorophenyl)-3-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)thiourea

-

-

1-(3-chlorophenyl)-3-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)urea

-

-

1-(3-methylbut-2-enyl)-5-m-tolyl-1H-indole

-

-

1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

Rattus norvegicus

-

22% inhibition

1-octyl-5-(3-methylphenyl)-1H-indole

-

a cysmethynil analogue

1-octyl-5-m-tolyl-1H-indole

-

-

1-octyl-5-m-tolyl-1H-indole-3-carboxamide

-

-

1-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methanamine

-

-

2'-methoxy-3',3''-diprenyl-licodione

-

isolated from Hovea parvicalyx, collected in Australia, structure determination, overview

2'-methoxy-3'-prenyllicodione

-

isolated from Hovea parvicalyx, collected in Australia, structure determination, overview

2-(1-octyl-1H-indol-3-yl)acetamide

-

-

2-(1-octyl-5-phenyl-1H-indol-3-yl)acetamide

-

-

2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-N-(3-methoxyphenyl)acetamide

-

-

2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-N-phenylacetamide

-

-

2-(5-(3-ethoxyphenyl)-1-octyl-1H-indol-3-yl)-N,N-diethylacetamide

-

-

2-(5-fluoro-1-(3-methylbut-2-enyl)-1H-indol-3-yl)acetamide

-

-

2-(5-fluoro-1-octyl-1H-indol-3-yl)acetamide

-

-

2-Carboxy-2'-hydroxy-5'-sulfoformazylbenzene

Saccharomyces cerevisiae

-

IC50: 1.1 mM

2-phenoxy-phenylfarnesylcysteine

-

low micromolar inhibitor

2-[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]acetamide

-

-

2-[1-[(2E,6E)-2,6-dimethylocta-2,6-dien-1-yl]-5-(3-methylphenyl)-1H-indol-3-yl]acetamide

-

-

2-[5-(2-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

2-[5-(3-ethoxyphenyl)-1-octyl-1H-indol-3-yl]-N,N-diethylacetamide

-

-

2-[5-(3-ethoxyphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

2-[5-(3-ethylphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

2-[5-(3-fluorophenyl)-1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]acetamide

-

-

2-[5-(3-fluorophenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

2-[5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(4-methylpiperazin-1-yl)ethan-1-one

-

-

2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(4-methylpiperazin-1-yl)ethanone

-

-

2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(piperidin-1-yl)ethan-1-one

-

-

2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(piperidin-1-yl)ethanone

-

-

2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(pyrrolidin-1-yl)ethan-1-one

-

-

2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(pyrrolidin-1-yl)ethanone

-

-

2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide

-

-

2-[5-(3-methylphenyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-1H-indol-3-yl]acetamide

-

-

2-[5-(3-methylphenyl)-1H-indol-3-yl]acetamide

-

-

2-[5-(4-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

2-[[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]sulfanyl]ethanol

-

-

2-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl](phenyl)amino]-1-(furan-2-yl)ethanone

-

-

2584 Da liver peptide

Rattus norvegicus

-

0.000071 mM, 50% inhibition

-

3,4-dichloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2Hpyran-4-yl)ethyl]aniline

-

-

3,5-dichloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline

-

-

3-(1-octyl-5-m-tolyl-1H-indol-3-yl)propanamide

-

-

3-(2,2-dimethyloxan-4-yl)-N-[(4-methoxyphenyl)methyl]-3-phenylpropan-1-amine

-

-

3-([(2E)-3-methyl-5-[4-(2-phenylethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid

-

75% residual activity at 0.01 mM

3-([(2E)-3-methyl-5-[4-(3-methylbutyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid

-

modest inhibitor, 72% residual activity at 0.01 mM

3-([(2E)-3-methyl-5-[4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid

-

poor inhibitor, 77% residual activity at 0.01 mM

3-([(2E)-3-methyl-5-[4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid

-

89% residual activity at 0.01 mM

3-([(2E)-3-methyl-5-[4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid

-

poor inhibitor, 80% residual activity at 0.01 mM

3-([(2E)-5-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoic acid

-

poor inhibitor, 87% residual activity at 0.01 mM

3-([(2E)-5-[4-(4-tert-butylphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoic acid

-

poor inhibitor, 88% residual activity at 0.01 mM

3-chloro-4-methyl-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)ethyl]aniline

-

-

3-chloro-4-methyl-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]aniline

-

-

3-chloro-N-(3-chlorophenyl)-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline

-

-

3-chloro-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)-ethyl]aniline

-

-

3-chloro-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline

-

-

3-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-4-methylaniline

-

-

3-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline

-

-

3-chloro-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline

-

-

3-fluoro-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)-ethyl]aniline

-

-

3-fluoro-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline

-

-

3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)-ethyl]aniline

-

-

3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline

-

-

3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline

-

-

3-methoxy-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline

-

-

3-methoxy-N-[2-[4-(4-methoxyphenyl)-2,2-dimethyltetrahydro-2H-pyran-4-yl]ethyl]aniline

-

-

3-methyl-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline

-

-

3-tert-butyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline

-

-

3-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethylamino]benzoic acid

-

-

3-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethylamino]phenol

-

-

3-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]phenol

-

-

3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]propanoic acid

-

modest inhibitor, 53% residual activity at 0.01 mM

3-[4-[(3E)-4,8-dimethylnona-3,7-dien-1-yl]-1H-1,2,3-triazol-1-yl]propanoic acid

-

modest inhibitor, 75% residual activity at 0.01 mM

3-[4-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-1H-1,2,3-triazol-1-yl]propanoic acid

-

modest inhibitor, 69% residual activity at 0.01 mM

3-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]propanamide

-

-

3-[[(2E)-3-methyl-5-(4-pentyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoic acid

-

modest inhibitor, 77% residual activity at 0.01 mM

3-[[(2E)-3-methyl-5-(4-phenyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoic acid

-

poor inhibitor, 88% residual activity at 0.01 mM

3-[[(2E)-3-methyl-5-(4-[2-[4-(thiophen-2-yl)phenyl]ethyl]-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoic acid

-

63% residual activity at 0.01 mM

3-[[(2E)-3-methyl-5-[4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl]propanoic acid

-

90% residual activity at 0.01 mM

3-[[(2E)-5-(4-benzyl-1H-1,2,3-triazol-1-yl)-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid

-

82% residual activity at 0.01 mM

3-[[(2E)-5-[4-[(biphenyl-4-yloxy)methyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid

-

75% residual activity at 0.01 mM

3-[[(2E)-5-[4-[2-(3'-cyanobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid

-

74% residual activity at 0.01 mM

3-[[(2E)-5-[4-[2-(4'-fluorobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid

-

42% residual activity at 0.01 mM

3-[[(2E)-5-[4-[2-(biphenyl-3-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid

-

74% residual activity at 0.01 mM

3-[[(2E)-5-[4-[2-(biphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid

-

43% residual activity at 0.01 mM

3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]-N,N-dimethylbenzenesulfonamide

-

-

3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzonitrile

-

-

4-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3-methylaniline

-

-

4-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline

-

-

4-hydroxyphenylglyoxal

Rattus norvegicus

-

48% inhibition

4-tert-butyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline

-

-

4-[(naphthalen-2-yl)(thiophen-2-yl)methylidene]oxane

competitive with the prenylated peptide substrate, N-acetyl-S-farnesyl cysteine and non-competitive with SAM

4-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]-N-methylbenzene-1-sulfonamide

-

-

4-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]butanoic acid

-

modest inhibitor, 83% residual activity at 0.01 mM

4-[4-[(3E)-4,8-dimethylnona-3,7-dien-1-yl]-1H-1,2,3-triazol-1-yl]butanoic acid

-

modest inhibitor, 90% residual activity at 0.01 mM

4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzenesulfonamide

-

-

4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzonitrile

-

-

5'-deoxymethylthioadenosine

-

-

5-(3-methylphenyl)-1-octyl-1H-indole-3-carboxamide

-

-

5-(3-methylphenyl)-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole

-

-

5-(3-methylphenyl)-1-octyl-3-(pyrrolidin-1-ylmethyl)-1H-indole

-

-

5-(3-methylphenyl)-1-octyl-3-[(piperidin-1-yl)methyl]-1H-indole

-

-

5-(3-methylphenyl)-1-octyl-3-[(pyrrolidin-1-yl)methyl]-1H-indole

-

-

5-(3-methylphenyl)-3-(morpholin-4-ylmethyl)-1-octyl-1H-indole

-

-

5-(3-methylphenyl)-3-[(4-methylpiperazin-1-yl)methyl]-1-octyl-1H-indole

-

-

5-(3-methylphenyl)-3-[(morpholin-4-yl)methyl]-1-octyl-1H-indole

-

-

5-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]-N,N-dimethylpyridin-2-amine

-

-

5-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]pyrimidin-2-amine

-

-

5-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]pyrimidine-2-carbonitrile

-

-

5-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]pentanoic acid

-

modest inhibitor, 73% residual activity at 0.01 mM

adenosine

-

plus homocysteine

aplysamine 6

show

biotin-Peg4-YIIKGVFWDPAC(C10-meta-Bp)

Saccharomyces cerevisiae

-

-

biotin-Peg4-YIIKGVFWDPAC(C10-para-Bp)

Saccharomyces cerevisiae

-

-

biotin-Peg4-YIIKGVFWDPAC(C5-meta-Bp)

Saccharomyces cerevisiae

-

-

biotin-Peg4-YIIKGVFWDPAC(C5-para-Bp)

Saccharomyces cerevisiae

-

-

Ca2+

-

moderate inhibition

CTAB

-

0.1%, more than 90% inhibition

Cu2+

-

complete inhibition

cysmethynil

show

deoxycholate

-

0.1%, 51% inhibition

diethylpyrocarbonate

Rattus norvegicus

-

96% inhibition

dimethylsulfoxid

-

more than 4% cause inhibition

ethyl 4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]amino]benzoate

-

-

ethyl [5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetate

-

-

FTI-2628

-

-

Hg2+

-

complete inhibition

iodoacetic acid

Rattus norvegicus

-

16% inhibition

methyl 3-([(2E)-3-methyl-5-[4-(2-phenylethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate

-

69% residual activity at 0.01 mM

methyl 3-([(2E)-3-methyl-5-[4-(3-methylbutyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate

-

modest inhibitor, 77% residual activity at 0.01 mM

methyl 3-([(2E)-3-methyl-5-[4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate

-

poor inhibitor, 82% residual activity at 0.01 mM

methyl 3-([(2E)-3-methyl-5-[4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate

-

89% residual activity at 0.01 mM

methyl 3-([(2E)-3-methyl-5-[4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate

-

poor inhibitor, 82% residual activity at 0.01 mM

methyl 3-([(2E)-5-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoate

-

poor inhibitor, 91% residual activity at 0.01 mM

methyl 3-([(2E)-5-[4-(4-tert-butylphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoate

-

poor inhibitor, 84% residual activity at 0.01 mM

methyl 3-[[(2E)-3-methyl-5-(4-nonyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate

-

modest inhibitor, 67% residual activity at 0.01 mM

methyl 3-[[(2E)-3-methyl-5-(4-pentyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate

-

modest inhibitor, 76% residual activity at 0.01 mM

methyl 3-[[(2E)-3-methyl-5-(4-phenyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate

-

poor inhibitor, 89% residual activity at 0.01 mM

methyl 3-[[(2E)-3-methyl-5-(4-[2-[4-(thiophen-2-yl)phenyl]ethyl]-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate

-

57% residual activity at 0.01 mM

methyl 3-[[(2E)-3-methyl-5-[4-[2-(1,1':4',1''-terphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl]propanoate

-

79% residual activity at 0.01 mM

methyl 3-[[(2E)-3-methyl-5-[4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl]propanoate

-

80% residual activity at 0.01 mM

methyl 3-[[(2E)-5-(4-benzyl-1H-1,2,3-triazol-1-yl)-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

80% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[(3E)-4,8-dimethylnona-3,7-dien-1-yl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

modest inhibitor, 59% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[(biphenyl-4-yloxy)methyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

67% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[2-(3'-cyanobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

30% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[2-(4'-fluorobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

28% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[2-(biphenyl-2-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

74% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[2-(biphenyl-3-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

65% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[2-(biphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

potent competitive inhibitor, 14% residual activity at 0.01 mM

methyl 3-[[(2E)-5-[4-[2-([1,1'-biphenyl]-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate

-

-

methyl ester of N-acetyl-S-farnesyl-L-cysteine

-

-

methyl [5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetate

-

-

methylthioadenosine

Leishmania donovani

-

0.9 mM, 50% inhibition

Mg2+

show

Mn2+

-

moderate inhibition

mono iodoacetate

-

moderate inhibition

N'-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N,N-dimethylbenzene-1,3-diamine

-

-

N,N'-dicyclohexylcarbodiimide

Rattus norvegicus

-

76% inhibition

N,N-diethyl-2-(5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl)acetamide

-

-

N,N-diethyl-2-[5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

N,N-diethyl-2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

N,N-dimethyl-1-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methanamine

-

-

N,N-dimethyl-2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide

-

-

N-((1-octyl-5-m-tolyl-1H-indol-3-yl)methyl)methanesulfonamide

-

-

N-(2-methylidenebut-3-en-1-yl)-2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide

-

-

N-(2-phenoxybenzoyl)-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine

-

35.9% inhibition at 0.01 mM

N-(2-phenoxybenzoyl)-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine

-

-

N-(3-chlorophenyl)-2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)acetamide

-

-

N-(3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]phenyl)acetamide

-

-

N-(5-methoxy-2-nitrobenzoyl)-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine

-

10.1% inhibition at 0.01 mM

N-(biphenyl-2-ylcarbonyl)-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine

-

17% inhibition at 0.01 mM

N-acetyl-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine

-

19.5% inhibition at 0.01 mM

N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine

show

N-acetyl-S-(3-(3-methylbut-2-enyl)-7,11-dimethyldodeca-2Z,6E,10-trien-1-yl)-L-cysteine

Saccharomyces cerevisiae

-

competitive inhibitor of overexpressed yeast Icmt

N-acetyl-S-(E,E)-farnesyl-L-cysteine

-

-

N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester

-

mixed-type vs. N-acetyl-S-(E,E)-farnesyl-L-cysteine

N-acetyl-S-(E,E)-geranylgeranyl-L-cysteine

-

-

N-acetyl-S-farnesyl-L-cysteine

show

N-acetyl-S-farnesyl-L-cysteine methyl ester

-

-

N-acetyl-S-farnesyl-L-cysteine methylester

-

noncompetitive inhibition with respect to biotin-S-farnesyl-L-cysteine, mixed type inhibition with respect to S-adenosyl-L-methionine

N-acetyl-S-geranylgeranyl-L-cysteine

show

N-acetyl-S-[(2E)-3-methyl-4-(4-phenoxyphenoxy)but-2-en-1-yl]-L-cysteine

-

15.5% inhibition at 0.01 mM

N-acetyl-S-[(2E)-3-methyl-4-[(naphthalen-2-ylamino)oxy]but-2-en-1-yl]-L-cysteine

-

14.5% inhibition at 0.01 mM

N-acetyl-S-[(2E)-3-methyl-5-(4-octylphenyl)pent-2-en-1-yl]-L-cysteine

-

31.1% inhibition at 0.01 mM

N-acetyl-S-[(2E)-3-methyl-5-(4-pentylphenyl)pent-2-en-1-yl]-L-cysteine

-

23.1% inhibition at 0.01 mM

N-acetyl-S-[(2E)-3-methyl-5-(4-propylphenyl)pent-2-en-1-yl]-L-cysteine

-

20.7% inhibition at 0.01 mM

N-acetyl-S-[(2E)-3-methyl-7-(4-phenoxyphenoxy)hept-2-en-1-yl]-L-cysteine

-

19.4% inhibition at 0.01 mM

N-acetyl-S-[(2E)-3-methyl-7-[(naphthalen-2-ylamino)oxy]hept-2-en-1-yl]-L-cysteine

-

22.4% inhibition at 0.01 mM

N-acetyl-S-[(2E)-4-(4-benzylphenoxy)-3-methylbut-2-en-1-yl]-L-cysteine

-

9.8% inhibition at 0.01 mM

N-acetyl-S-[(2E)-5-(4-hexylphenyl)-3-methylpent-2-en-1-yl]-L-cysteine

-

18.8% inhibition at 0.01 mM

N-acetyl-S-[(2Z)-4-(biphenyl-4-yl)-3-phenylbut-2-en-1-yl]-L-cysteine

-

26.6% inhibition at 0.01 mM

N-benzyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]furan-2-carboxamide

-

-

N-bromosuccinimide

Rattus norvegicus

-

56% inhibition in the presence of S-adenosyl-L-homocysteine, 87% inhibition in the absence of S-adenosyl-L-homocysteine

N-ethyl-N-((1-(3-methylbut-2-enyl)-1H-indol-3-yl)methyl) ethanamine

-

-

N-ethyl-N-((5-fluoro-1-(3-methylbut-2-enyl)-1H-indol-3-yl)methyl)ethanamine

-

-

N-ethyl-N-([1-octyl-5-[3-(trifluoromethyl)phenyl]-1H-indol-3-yl]methyl)ethanamine

-

-

N-ethyl-N-([5-[4-(methanesulfonyl)phenyl]-1-octyl-1H-indol-3-yl]methyl)ethanamine

-

-

N-ethyl-N-[(4-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine

-

-

N-ethyl-N-[(5-fluoro-1-octyl-1H-indol-3-yl)methyl]-ethanamine

-

-

N-ethyl-N-[(5-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine

-

-

N-ethyl-N-[(6-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine

-

-

N-ethyl-N-[(7-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine

-

-

N-ethyl-N-[[1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[1-octyl-5-(pyridin-3-yl)-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[1-octyl-5-(pyrimidin-5-yl)-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[5-(2-fluorophenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[5-(2-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[5-(3-fluorophenyl)-1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[5-(3-fluorophenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[5-(3-fluoropyridin-4-yl)-1-octyl-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine

-

-

720184, 733780, 734514

N-ethyl-N-[[5-(4-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine

-

-

N-ethylmaleimide

show

N-methyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]propan-2-amine

-

-

n-octyl beta-glucoside

-

0.2%, 55-75% inhibition

N-[(1-octyl-5-m-tolyl-1H-indol-3-yl)methyl]acetamide

-

-

N-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide

-

-

N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)-ethyl]aniline

-

-

N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-2-methylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3,4-dimethoxyaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3,5-dimethylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-(trifluoromethoxy)aniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-(trifluoromethyl)aniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-ethylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-fluoroaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-isopropylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methoxy-4-methylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methoxyaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-(trifluoromethoxy)aniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-fluoroaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-isopropylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-methoxyaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-methylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N,3-dimethylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N-methylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N-phenylacetamide

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]aniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3,4-dimethylaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3-nitroaniline

-

-

N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-4-nitroaniline

-

-

N-[2-(benzyloxy)benzoyl]-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine

-

-

N-[3-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-(2-methoxyphenyl)propyl]-N-(4-methoxybenzyl)furan-2-carboxamide

-

the inhibitor is competitive with respect to a prenylated methyl acceptor substrate but noncompetitive toward the S-adenosyl-L-methionine

N-[3-(phenylsulfonyl)propanoyl]-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine

-

22.7% inhibition at 0.01 mM

N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-(propan-2-yl)propan-2-amine

-

-

N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-propylpropan-1-amine

-

-

N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]acetamide

-

-

N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]methanesulfonamide

-

-

Nonidet P40

-

0.1%, 73% inhibition

Phenylglyoxal

Rattus norvegicus

-

74% inhibition, inhibition increases with the alkanity of the preincubation medium, S-adenosyl-L-methionine protects against inhibition

retinoic acid

-

20% decrease of N-acetyl-S-(E,E)-farnesyl-L-cysteine methylation in cells treated with 0.01 mM retinoic acid

S-(Geranylgeranyl-2-thio)acetic acid

-

-

S-adenosyl-L-homocysteine

show

S-adenosylethionine

-

-

S-farnesyl thiosalicylic acid

show

S-farnesyl-4-chlorothiosalicylic acid

Rattus norvegicus

-

-

S-farnesyl-4-fluorothiosalicylic acid

Rattus norvegicus

-

-

S-farnesyl-5-chlorothiosalicylic acid

Rattus norvegicus

-

-

S-farnesyl-5-fluorothiosalicylic acid

Rattus norvegicus

-

-

S-Farnesylthioacetic acid

show

S-[(2E)-3-[2-([1,1'-biphenyl]-4-yl)ethyl]-6-methylhepta-2,5-dien-1-yl]-N-(2-phenoxybenzoyl)-L-cysteine

-

-

S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine

-

-

S-{(2E)-3-[2-(biphenyl-4-yl)ethyl]-6-methylhepta-2,5-dien-1-yl}-N-(2-phenoxybenzoyl)-L-homocysteine

-

low micromolar inhibitor

sinefungin

show

spermatinamine

-

-

Triton X-100

-

0.1%, 63% inhibition

Tween 80

-

0.1%, 33% inhibition

Zn2+

-

complete inhibition

[2-(2,2-dimethyl-4-p-tolyltetrahydropyran-4-yl)ethyl]-(3-methoxyphenyl)amine

-

-

[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-(2-fluorophenyl)amine

-

-

[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]-(2-fluoro-4-methylphenyl)amine

-

-

[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]-(3-fluoro-4-methoxyphenyl)amine

-

-

[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)-ethyl]-(3-methoxyphenyl)amine

-

-

[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)-ethyl]phenylamine

-

-

[2-[4-(3-chlorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine

-

-

[2-[4-(3-fluoro-phenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine

-

-

[2-[4-(4-chlorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine

-

-

[2-[4-(4-fluorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine

-

-

[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]acetic acid

-

modest inhibitor, 65% residual activity at 0.01 mM

additional information

show

-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)